Algert Global LLC Grows Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Algert Global LLC grew its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 46.2% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 516,209 shares of the biotechnology company's stock after purchasing an additional 163,076 shares during the quarter. Algert Global LLC owned approximately 0.25% of BioCryst Pharmaceuticals worth $3,923,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. boosted its stake in BioCryst Pharmaceuticals by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company's stock worth $57,000 after acquiring an additional 1,322 shares in the last quarter. Xponance Inc. increased its holdings in BioCryst Pharmaceuticals by 13.1% during the 2nd quarter. Xponance Inc. now owns 12,980 shares of the biotechnology company's stock worth $80,000 after acquiring an additional 1,505 shares during the period. Creative Planning grew its position in shares of BioCryst Pharmaceuticals by 5.9% during the 3rd quarter. Creative Planning now owns 49,347 shares of the biotechnology company's stock valued at $375,000 after purchasing an additional 2,734 shares in the last quarter. CWM LLC increased its holdings in shares of BioCryst Pharmaceuticals by 200.0% in the second quarter. CWM LLC now owns 5,658 shares of the biotechnology company's stock worth $35,000 after purchasing an additional 3,772 shares during the period. Finally, Diversified Trust Co raised its position in shares of BioCryst Pharmaceuticals by 18.0% in the second quarter. Diversified Trust Co now owns 24,752 shares of the biotechnology company's stock worth $153,000 after buying an additional 3,774 shares in the last quarter. 85.88% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Trading Down 4.3 %

BCRX traded down $0.33 during trading on Tuesday, reaching $7.27. The stock had a trading volume of 3,860,355 shares, compared to its average volume of 2,926,777. The stock's 50 day moving average is $7.64 and its two-hundred day moving average is $7.26. The company has a market capitalization of $1.51 billion, a price-to-earnings ratio of -11.92 and a beta of 1.89. BioCryst Pharmaceuticals, Inc. has a one year low of $4.03 and a one year high of $8.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share for the quarter, meeting the consensus estimate of ($0.07). The company had revenue of $117.10 million for the quarter, compared to the consensus estimate of $113.99 million. During the same quarter in the previous year, the business earned ($0.19) earnings per share. BioCryst Pharmaceuticals's revenue was up 35.1% compared to the same quarter last year. On average, equities research analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on BCRX. JMP Securities upped their target price on BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the stock a "market outperform" rating in a research note on Tuesday, August 6th. StockNews.com upgraded BioCryst Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Tuesday, August 6th. Barclays lifted their price target on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an "equal weight" rating in a research report on Tuesday, November 5th. Needham & Company LLC reiterated a "buy" rating and set a $14.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $15.60.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.